Cover Image
Market Research Report

Asia Pacific Cancer Immunotherapy Market (2018 - 2024)

Published by KBV Research Product code 763726
Published Content info 86 Pages
Delivery time: 1-2 business days
Price
Back to Top
Asia Pacific Cancer Immunotherapy Market (2018 - 2024)
Published: December 20, 2018 Content info: 86 Pages
Description

The Asia Pacific Market would witness market growth of 16.5% CAGR during the forecast period (2018 - 2024). Cancer immunotherapy is the type of cancer treatment helping the immune system fight cancer. There are various kinds of cancer immunotherapies used and they are monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Growing patient population that is suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other cancers are the factors that drive the global cancer immunotherapy market. Additionally, growing geriatric population and governmental contribution to healthcare expenditure are some other factors that add to the market growth.

Based on technology, the market is segmented into Monoclonal Antibodies, Cytokines & Immunomodulators and other technology. Based on application, the market is segmented into Lung cancer, Breast cancer, Colorectal, Prostate cancer, Head & Neck cancer and other application. Based on end user the market is segmented into Hospitals, Clinics and other end user. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AstraZeneca, Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Bristol-Myers Squibb Company, Pfizer Inc., Bayer Ag, Immunomedics Inc., Novartis AG, F. Hoffmann-La Roche Ltd

Table of Contents

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 Asia Pacific Cancer Immunotherapy Market, by Technology
    • 1.4.2 Asia Pacific Cancer Immunotherapy Market, by Application
    • 1.4.3 Asia Pacific Cancer Immunotherapy Market, by End User
    • 1.4.4 Asia Pacific Cancer Immunotherapy Market, by Countries
  • 1.5 Methodology for the research

Chapter 2. Market Overview

  • 2.1 Introduction
  • 2.2 Key Factors Impacting the Market
    • 2.2.1 Market Drivers
    • 2.2.2 Market Restraints

Chapter 3. Asia Pacific Cancer Immunotherapy Market by Technology

    • 3.1.1 Asia Pacific Monoclonal Antibodies Cancer Immunotherapy Market by Country
    • 3.1.2 Asia Pacific Cytokines & Immunomodulators Cancer Immunotherapy Market by Country
    • 3.1.3 Asia Pacific Other Technology Cancer Immunotherapy Market by Country

Chapter 4. Asia Pacific Cancer Immunotherapy Market by Application

    • 4.1.1 Asia Pacific Cancer Immunotherapy Lung Cancer Market by Country
    • 4.1.2 Asia Pacific Cancer Immunotherapy Breast Cancer Market by Country
    • 4.1.3 Asia Pacific Cancer Immunotherapy Colorectal Cancer Market by Country
    • 4.1.4 Asia Pacific Cancer Immunotherapy Melanoma Market by Country
    • 4.1.5 Asia Pacific Cancer Immunotherapy Prostate Cancer Market by Country
    • 4.1.6 Asia Pacific Cancer Immunotherapy Head & Neck Cancer Market by Country
    • 4.1.7 Asia Pacific Other Application Cancer Immunotherapy Market by Country

Chapter 5. Asia Pacific Cancer Immunotherapy Market by End User

    • 5.1.1 Asia Pacific Hospitals Cancer Immunotherapy Market by Country
    • 5.1.2 Asia Pacific Clinics Cancer Immunotherapy Market by Country
    • 5.1.3 Asia Pacific Other End User Cancer Immunotherapy Market by Country

Chapter 6. Asia Pacific Cancer Immunotherapy Market by Country

  • 6.1 China Cancer Immunotherapy Market
    • 6.1.1 China Cancer Immunotherapy Market by Technology
    • 6.1.2 China Cancer Immunotherapy Market by Application
    • 6.1.3 China Cancer Immunotherapy Market by End User
  • 6.2 Japan Cancer Immunotherapy Market
    • 6.2.1 Japan Cancer Immunotherapy Market by Technology
    • 6.2.2 Japan Cancer Immunotherapy Market by Application
    • 6.2.3 Japan Cancer Immunotherapy Market by End User
  • 6.3 India Cancer Immunotherapy Market
    • 6.3.1 India Cancer Immunotherapy Market by Technology
    • 6.3.2 India Cancer Immunotherapy Market by Application
    • 6.3.3 India Cancer Immunotherapy Market by End User
  • 6.4 South Korea Cancer Immunotherapy Market
    • 6.4.1 South Korea Cancer Immunotherapy Market by Technology
    • 6.4.2 South Korea Cancer Immunotherapy Market by Application
    • 6.4.3 South Korea Cancer Immunotherapy Market by End User
  • 6.5 Singapore Cancer Immunotherapy Market
    • 6.5.1 Singapore Cancer Immunotherapy Market by Technology
    • 6.5.2 Singapore Cancer Immunotherapy Market by Application
    • 6.5.3 Singapore Cancer Immunotherapy Market by End User
  • 6.6 Malaysia Cancer Immunotherapy Market
    • 6.6.1 Malaysia Cancer Immunotherapy Market by Technology
    • 6.6.2 Malaysia Cancer Immunotherapy Market by Application
    • 6.6.3 Malaysia Cancer Immunotherapy Market by End User
  • 6.7 Rest of Asia Pacific Cancer Immunotherapy Market
    • 6.7.1 Rest of Asia Pacific Cancer Immunotherapy Market by Technology
    • 6.7.2 Rest of Asia Pacific Cancer Immunotherapy Market by Application
    • 6.7.3 Rest of Asia Pacific Cancer Immunotherapy Market by End User

Chapter 7. Company Profiles

  • 7.1 Amgen Inc.
    • 7.1.1 Company Overview
    • 7.1.2 Financial Analysis
    • 7.1.3 Segmental & Regional Analysis
    • 7.1.4 Research and Development Expense
  • 7.2 Merck & Company, Inc.
    • 7.2.1 Company Overview
    • 7.2.2 Financial Analysis
    • 7.2.3 Regional and Segmental Analysis
    • 7.2.4 Research & Development
  • 7.3 Pfizer Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental &Regional Analysis
    • 7.3.4 Revenue analysis by Region
    • 7.3.5 Research and Development
  • 7.4 Immunomedics Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Analysis
    • 7.4.3 Revenue Analysis by Region
    • 7.4.4 Research and Development
  • 7.5 Astrazeneca Plc.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Analysis
    • 7.5.3 Segmental analysis
    • 7.5.4 Research & Development
  • 7.6 F. Hoffmann-La Roche Ltd.
    • 7.6.1 Company Overview
    • 7.6.2 Financial Analysis
    • 7.6.3 Revenue & Segment analysis
    • 7.6.4 Research and Development
  • 7.7 Eli Lilly and Company
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Segmental and Regional Analysis
    • 7.7.4 Research & Development Expense
  • 7.8 Novartis AG
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Segmental and Regional Analysis
    • 7.8.4 Research & Development Expense
  • 7.9 Bristol-Myers Squibb Company
    • 7.9.1 Company Overview
  • 7.1 Bayer AG
    • 7.10.1 Company Overview
    • 7.10.2 Financial Analysis
    • 7.10.3 Segmental and Regional Analysis
    • 7.10.4 Research & Development Expense

LIST OF TABLES

  • TABLE 1 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 2 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 3 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 4 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 5 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 6 ASIA PACIFIC MONOCLONAL ANTIBODIES CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 7 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 8 ASIA PACIFIC CYTOKINES & IMMUNOMODULATORS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 9 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 10 ASIA PACIFIC OTHER TECHNOLOGY CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 11 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 12 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 13 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 14 ASIA PACIFIC CANCER IMMUNOTHERAPY LUNG CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 15 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 16 ASIA PACIFIC CANCER IMMUNOTHERAPY BREAST CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 17 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 18 ASIA PACIFIC CANCER IMMUNOTHERAPY COLORECTAL CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 19 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 20 ASIA PACIFIC CANCER IMMUNOTHERAPY MELANOMA MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 21 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 22 ASIA PACIFIC CANCER IMMUNOTHERAPY PROSTATE CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 23 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 24 ASIA PACIFIC CANCER IMMUNOTHERAPY HEAD & NECK CANCER MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 25 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 26 ASIA PACIFIC OTHER APPLICATION CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 27 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 28 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 29 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 30 ASIA PACIFIC HOSPITALS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 31 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 32 ASIA PACIFIC CLINICS CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 33 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 34 ASIA PACIFIC OTHER END USER CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 35 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2014 - 2017, USD MILLION
  • TABLE 36 ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY COUNTRY, 2018 - 2024, USD MILLION
  • TABLE 37 CHINA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 38 CHINA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 39 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 40 CHINA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 41 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 42 CHINA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 43 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 44 CHINA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 45 JAPAN CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 46 JAPAN CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 47 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 48 JAPAN CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 49 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 50 JAPAN CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 51 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 52 JAPAN CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 53 INDIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 54 INDIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 55 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 56 INDIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 57 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 58 INDIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 59 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 60 INDIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 61 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 62 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 63 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 64 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 65 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 66 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 67 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 68 SOUTH KOREA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 69 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 70 SINGAPORE CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 71 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 72 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 73 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 74 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 75 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 76 SINGAPORE CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 77 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 78 MALAYSIA CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 79 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 80 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 81 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 82 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 83 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 84 MALAYSIA CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 85 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2014 - 2017, USD MILLION
  • TABLE 86 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET, 2018 - 2024, USD MILLION
  • TABLE 87 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2014 - 2017, USD MILLION
  • TABLE 88 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY TECHNOLOGY, 2018 - 2024, USD MILLION
  • TABLE 89 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2014 - 2017, USD MILLION
  • TABLE 90 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY APPLICATION, 2018 - 2024, USD MILLION
  • TABLE 91 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2014 - 2017, USD MILLION
  • TABLE 92 REST OF ASIA PACIFIC CANCER IMMUNOTHERAPY MARKET BY END USER, 2018 - 2024, USD MILLION
  • TABLE 93 KEY INFORMATION-AMGEN INC.
  • TABLE 94 KEY INFORMATION-MERCK & COMPANY INC.
  • TABLE 95 KEY INFORMATION- PFIZER INC.
  • TABLE 96 KEY INFORMATION- IMMUNOMEDICS INC.
  • TABLE 97 KEY INFORMATION- ASTRAZENECA PLC.
  • TABLE 98 KEY INFORMATION- F. HOFFMANN-LA ROCHE LTD.
  • TABLE 99 KEY INFORMATION - ELI LILLY AND COMPANY
  • TABLE 100 KEY INFORMATION - NOVARTIS AG
  • TABLE 101 KEY INFORMATION - BRISTOL-MYERS SQUIBB COMPANY
  • TABLE 102 KEY INFORMATION - BAYER AG
Back to Top